Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px
Document › Details

AB Sciex. (9/17/12). "Press Release: AB Sciex Announces Biologics Initiative. Mass Spectrometry Leader’s Biologics Focus Programs Address Industry Shift to Biopharmaceuticals". Framingham, MA.

Organisation Organisation AB Sciex LLC
  Group Danaher (Group)
Products Product mass spectrometry-based analysis of biopharmaceutical
  Product 2 IMSC 2012 Kyoto
Persons Person Blair, Rainer M. (Danaher 201403– VP + Head Life Sciences Business before President AB Sciex + Videojet + MAPEI + BASF)
  Person 2 Petrucci, Anthony (Philanthropy 201404– Director Communications before Danaher 20101–201404 Director Global PR)
     


AB SCIEX, a global leader in life science analytical technologies, today announced a global initiative focused on biologics. This new initiative is in response to the fundamental shift of the pharmaceutical industry into biopharmaceutical development. AB SCIEX's BiologicsFocus Initiative consists of four components: new product development; beta software evaluation program; one-on-one connections program; and forums for sharing the latest advancements in biologics across the scientific community. The company revealed this initiative today at the International Mass Spectrometry Conference (IMSC) in Japan.

The BiologicsFocus Initiative represents AB SCIEX's open approach to producing comprehensive biologics solutions by involving scientists in industry and academia in the development of new tools. AB SCIEX already has a proven track record with its TripleTOF technology for bio-therapeutics characterization. The company is now taking the next important step to address an industry-wide need - the development of data analysis solutions to simplify and accelerate biologics development.

Forty-two percent of new drugs in drug development pipelines of pharmaceutical companies are based on biologics, according to survey results published earlier this year by EvaluatePharma, a market research firm. Moreover, the development of biosimilars, or "generic" biologic drugs, is dramatically increasing globally in response to legislation enabling their licensure in the United States.

The trend is to transition away from the traditional model of drug development, which is based on small molecule analysis. The promise of biopharmaceuticals is that pharmaceutical companies will be able to more rapidly develop more effective drugs with fewer side effects. Recent advancements in technologies for large molecule analysis, such as protein characterization, have sped up the shift to bio-therapeutics.

AB SCIEX's biologics initiative includes the following programs:

> BiologicsFocus Innovation - AB SCIEX is developing a suite of new products specifically for biologics. Because data analysis is considered to be a bottleneck for this type of analysis today, the company is focusing on software development in the first phase of this initiative to eliminate this bottleneck.

> BiologicsFocus Eval - AB SCIEX is actively developing new biologics characterization software. To participate in a beta software evaluation program, go to www.absciex.com/biologics.

> BiologicsFocus Summits - AB SCIEX will host information-sharing forums or "summits" as special events that will bring together opinion leaders who are driving the evolution of biopharmaceuticals. This will also include an advisory network of scientists to provide input and feedback for ongoing product development.

> BiologicsFocus Connections - AB SCIEX will connect biologics researchers one-on-one with each other to cultivate new collaborations and advance this field of pharmaceutical science.

"We recognize biologics for its strategic importance to the pharmaceutical industry," said Rainer Blair, President of AB SCIEX. "AB SCIEX is well-positioned with our industry-leading hardware platforms and our unique combination of strengths in both large molecule characterization and pharmaceutical analysis. We are working closely with pharmaceutical scientists to develop and shape new software solutions that directly address the needs and requirements for the new frontier of drug discovery and development. We continue to be a trusted partner with pharmaceutical companies and academics worldwide."


About AB SCIEX

AB SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to push the limits in their field and address the complex analytical challenges they face. The company's global leadership and world-class service and support in the mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With over 25 years of proven innovation, AB SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information about the company, go to www.absciex.com. Follow AB SCIEX on LinkedIn, Twitter @ABSCIEX, Facebook and LinkedIn.

AB Sciex Instruments Are For Research Use Only. Not for use in diagnostic procedures. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEXTM is being used under license.


Media Contact

Anthony Petrucci
AB SCIEX
1.508.383.7961
anthony.petrucci@absciex.com

   
Record changed: 2016-03-19

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for Danaher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px